JERUSALEM, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (DRTS) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®, today announced that the ...

- FDA approval marks Alpha Tau’s fifth simultaneous active U.S. IDE as the Company expands Alpha DaRT’s reach into recurrent prostate cancer - ...

Dr Fred Saad of the University of Montreal discusses the future direction of alpha emitter agents in the treatment of prostate cancer, emphasizing the logical progression of resea ...

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the novel Phase 2 design of the ongoing TheraPb clinical trial of ...

Alpha Tau Medical Ltd (DRTS) announced an update on their ongoing clinical study. Study Overview – Alpha Tau Medical Ltd. (NASDAQ: DRTS) is launching a new safety study titled “A Safety Study of ...

Nearly three years of research have brought about remarkable results for the majority of 80 patients subjected to targeted alpha therapy of metastatic prostate cancer. The first assessments - ...

Prospective External Validation of the Esbenshade Vanderbilt Models Accurately Predicts Bloodstream Infection Risk in Febrile Non-Neutropenic Children With Cancer Following investigational new ...

Bayer presents positive results from global phase I first-in-human, dose-escalation PAnTHa study at ASCO GU 2026: Berlin, Germany Monday, March 2, 2026, 13:00 Hrs [IST] Bayer anno ...

Clinical development of 212Pb-ADVC001 (ADVC001) is advancing rapidly with encouraging Phase 1b data presented at ESMO 2025 The Phase 2 expansion will evaluate 160 MBq and 200 MBq doses of ADVC001 ...